Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 10, 2006, Pages 3479-3484

  Waites, Ken B ^a   Duffy, Lynn B ^a   Dowzicky, Michael J ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HOSPITALIZATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POPULATION SURVEILLANCE; UNITED STATES;

EID: 33749520469     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00210-06     Document Type: Article

References (18)

1. Babinchak, T., E. Ellis-Grosse, N. Dartois, G. M. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41:8354-8367.
2. Barrett, J. F. 2005. MRSA - what is it, and how do we deal with the problem? Expert Opin. Ther. Targets 9:253-265.
3. Biedenbach, D. J., G. J. Moet, and R. N. Jones. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream isolates from the SENTRY antimicrobial surveillance program (1997-2002). Diagn. Microbiol. Infect. Dis. 50:59-69.
4. Bradford, P. A., D. T. Weaver-Sands, and P. J. Petersen. 2005. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41:S315-S332.
5. Bratu, S., M. Mooty, S. Nichani, D. Landman, C. Gullans, B. Pettinato, U. Karumudi, P. Tolaney, and J. Quale. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49:3018-3020.
6. Bratu, S., D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam, and J. Quale. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City. Arch. Intern. Med. 165:1430-1435.
7. Bratu, S., P. Tolaney, U. Karumudi, J. Quale, M. Mooty, S. Nichani, and D. Landman. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, N.Y.: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132.
8. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing, document M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
9. Gaynes, R., and J. R. Edwards. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
10. Joly-Guillou, M. L. 2005. Clinical impact and pathogenicity of Acinetobacter. Clin. Microbiol. Infect. 11:868-873.
11. Jones, M. E., D. C. Draghi, C. Thornsberry, J. A. Karlowsky, D. F. Sahm, and R. P. Wenzel. 2004. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American surveillance study (2000-2002). Ann. Clin. Microbiol. Antimicrob. 3:14 [Online.] http://www .ann-clinmicrob.com/content/3/1/14.
12. Karlowsky, J. A., M. E. Jones, D. C. Draghi, C. Thornsberry, D. F. Sahm, and G. A. Volturo. 2004. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann. Clin. Microbiol. Antimicrob. 3:7 [Online.] http://www .ann-clinmicrob.com/content/3/1/7.
13. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. document M7-A6. National Committee for Clinical Laboratory' Standards, Wayne, Pa.
14. Paterson, D. L., F. Rossi, F. Baquero, P.-R. Hsueh, G. L. Woods, V. Satishchandran, T. A. Snyder, C. M. Harvey, H. Teppler, M. J. DiNubile, and J. W. Chow. 2005. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 study for monitoring antimicrobial resistance trends. J. Antimicrob. Chemother. 55:965-973.
15. Rhomberg, P. R., T. R. Pritsche, H. S. Sader, and R. N. Jones. 2005. Comparative antimicrobial potency of meropenem tested against gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J. Chemother. 17:459-469.
16. Sader, H. S., R. N. Jones, M. J. Dowzicky, and T. R. Fritsche. 2005. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 52:203-208.
17. Streit, J. M., R. N. Jones, H. S. Sader, and T. R. Fritsche. 2004. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY antimicrobial surveillance program. Int. J. Antimicrob. Agents 24:111-118.
18. Wyeth Pharmaceuticals. 2005. Tygacil product insert. Wyeth Pharmaceuticals, Philadelphia, Pa. [Online.] http://www.tygacil.com.